Journey Medical Q3 2025 revenue $17.6M (+21% YoY); Emrosi sales $4.9M, prescriptions up 146%

Journey Medical Corp

2025-Q3 EPS reported -$0.43 vs consensus -$0.05 ▼ miss (-786.6%)

Q3 2025 net revenues $17.6M, up 21% YoY from $14.6M; driven by Emrosi launch.
Emrosi net sales $4.9M; prescriptions increased 146% sequentially vs Q2 2025.
Net loss narrowed to $2.3M ($0.09/sh) from $2.4M ($0.12/sh) in Q3 2024.
Adjusted EBITDA improved to positive $1.7M vs $0.3M in prior-year quarter.
Gross margin 67.4% vs 69.4% in Q3 2024 (prior year benefited from one-time adjustments).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.